More on Sarepta Q1 results

Sarepta Therapeutics (SRPT) revenue from grants/research: $6.1M (+35.6%); operating loss: ($25.1M) (-63%); net loss: ($28.3M) (+32.8%); loss/share: ($0.75) (+43.2%); quick assets: $225.2M (-12.4%).

Eteplirsen NDA submission expected by year end.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs